VISTAGEN THERAPEUTICS, INC. Proceeds from Issuance of Debt
VISTAGEN THERAPEUTICS, INC. (VTGN) reported Proceeds from Issuance of Debt of $7.17 million for the 184-month period ending 2014-03-31, per its 10-K filed 2014-06-25.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfDebt · last filed 2015-06-29
- VISTAGEN THERAPEUTICS, INC. proceeds from issuance of debt for the quarter ending 2014-03-31 was $0.00, a 100.00% decline year-over-year.
- VISTAGEN THERAPEUTICS, INC. proceeds from issuance of debt for the quarter ending 2013-03-31 was $1.00M.
- VISTAGEN THERAPEUTICS, INC. proceeds from issuance of debt for fiscal 2014 was $250.00K, a 92.24% decline from fiscal 2013.
- VISTAGEN THERAPEUTICS, INC. proceeds from issuance of debt for fiscal 2013 was $3.22M.
| Period end | Proceeds from Issuance of Debt 3 month | Proceeds from Issuance of Debt 9 month | Proceeds from Issuance of Debt 12 month | Proceeds from Issuance of Debt 181 month | Proceeds from Issuance of Debt 184 month |
|---|---|---|---|---|---|
| 2014-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-06-29 | $250.00K 10-K · filed 2015-06-29 | $7.17M 10-K · filed 2014-06-25 | ||
| 2013-12-31 | $250.00K 10-Q · filed 2014-02-14 | $7.17M 10-Q · filed 2014-02-14 | |||
| 2013-03-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2014-06-25 | $3.22M 10-K · filed 2014-06-25 | |||
| 2012-12-31 | $2.22M 10-Q · filed 2014-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |